Episode
Cell Therapy Advances And Biotech Leadership With Nkarta's Paul Hastings
- Podcast
- Business Of Biotech
- Published
- Aug 10, 2026
- Duration seconds
- 3026
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/cell-therapy-advances-and-biotech-leadership-with-nkarta-s-paul-hastings/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/business-of-biotech-123501/cell-therapy-advances-and-biotech-leadership-with-nkarta-s-paul-hastings.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Paul Hastings, Founding CEO and Board Member at Nkarta, an allogeneic cell therapy developer, talks about building off-the-shelf CAR NK cell therapies for autoimmune disease. Paul is candid about problems with clinical trial infrastructure in the U.S., what it will take to fix trial access (biotechs should actively facilitate patient access to trials and work with community health center...